How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


Bioneer co-authors review on newest developments in the cancer biomarker area

The “First International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation”, was held in Trondheim, Norway June 2016. Boye Schnack Nielsen, who is a well recognized Bioneer expert in molecular pathology contributed to a conference based review on the critital role of biomarker analysis in the area of indivualized therapy and precision medicine.

Read more
Søren Carlsen joins Bioneer as Director of the Board

Bioneer welcomes Søren Carlsen as new Director of the Board. Thereby the Board includes an experienced and well-recognized person, who knows the Danish Life Science industry inside out.

Read more
New P-glycoprotein cell line to predict blood brain barrier permeability of drugs

Bioneer offers a new service to assess the permeability of a drug across the blood-brain barrier. The cell line is characterized by producing large amounts of P-glycoprotein.

Read more

Meet us at:

Biomarker Agora, Nov 1th 2016 in Copenhagen

Bioneer develops biomarker tools including especially in situ technologies for the biomarker/precision medicine area. Bioneer  will present a range of its novel R & D projects at the meeting.

Read more
Cancer Crosslinks - Oct 19th 2016 in Lund
Bioneer participates in Cancer Crosslinks - a cross disciplinary meeting on different aspects of cancer.
Read more
Other places to meet us